Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215633 | 0.73 | CHRM2 (0.42) | CHRM1 | |
| SCHEMBL4191884 | 0.73 | CHRM2 (0.42) | CHRM1 | |
| SCHEMBL4037913 | 0.72 | CYP19A1 (0.35) | CYP19A1SIGMAR1CHRM1FAAH | |
| SCHEMBL4043275 | 0.69 | CYP19A1 (0.34) | CYP19A1SIGMAR1 | |
| SCHEMBL28339063 | 0.68 | RAB9A (0.38) | CYP19A1SIGMAR1CHRM1FAAH | |
| SCHEMBL15322317 | 0.67 | RAB9A (0.39) | CYP19A1SIGMAR1CHRM1 | |
| SCHEMBL2980833 | 0.67 | SIGMAR1 (0.41) | CYP19A1SIGMAR1CHRM1FAAH | |
| SCHEMBL6235471 | 0.67 | CYP19A1 (0.31) | CYP19A1CHRM1FAAH | |
| SCHEMBL15996086 | 0.66 | ALDH1A1 (0.33) | CYP19A1 | |
| SCHEMBL14458907 | 0.66 | ALDH1A1 (0.38) | CYP19A1SIGMAR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CYP19A1 1136/4885SIGMAR1 958/4885CHRM1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.